Zentalis Pharmaceuticals, Inc.
ZNTL
Zentalis Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on discovering and developing small molecule therapeutics for the treatment of various cancers. Its lead product candidate includes the ZN-c3, an inhibitor of WEE1, a protein tyrosine kinase, which is in Phase 2 clinical trial for the treatment of advanced solid tumors; Phase 1/2 clinical trial for the treatment ofā¦ read more
Healthcare
Biotechnology
5 years
USD
Exclusive to Premium users
Price
per share adjusted in USD$1.33
Price+0.76%
$0.01
1Y
Price
Market Cap
$96.094m
Small
Price/Earnings 3y Avg5y Avg
-
Premium
Premium
Financials Overview
Key metrics over the past few years-
EBITDA Margin-
Net Profit Margin-
Free Cash Flow MarginRevenue
$26.865m
-60.2%
1y CAGR-20.0%
3y CAGR-15.0%
5y CAGREarnings
-$162.783m
+1.8%
1y CAGR+7.2%
3y CAGR-6.9%
5y CAGREPS
-$2.27
+2.6%
1y CAGR+16.9%
3y CAGR+7.6%
5y CAGRBook Value
$274.495m
$351.707m
Assets$77.212m
Liabilities$37.690m
DebtDebt to Assets
10.7%
-0.2x
Debt to EBITDAFree Cash Flow
-$151.091m
+11.7%
1y CAGR+1.4%
3y CAGR+0.1%
5y CAGRFinancial Reports
Earnings and other important metrics. Amounts in USD.No items found.
Press Releases
Statements and updates from the company